Gennova mRNA vaccine stable above sub-zero temperatures unlike global peers

The messenger RNA vaccine candidate contains a short, synthetic version encoding the spike protein (antigen) of the novel coronavirus Sars-CoV-2

Pune-based Gennova Biopharmaceuticals' Covid-19 vaccine candidate HGCO19, India's first messenger ribonucleic acid (mRNA) platform-based vaccine, will remain stable at 2-8 degrees Celsius, unlike its global peers - BNT162b2 (from Pfizer-BioNTech) and mRNA-1273 (from Moderna) - that require sub-zero temperatures.

The company received conditional permission for Phases 1 and 2 human clinical trial of the Covid-19 vaccine developed by it after the subject expert committee (SEC) deliberated on its proposal. 

The firm presented its proposal, along with data from the animal toxicity study, before the SEC, which granted permission for Phases 1 and 2 clinical trial on the condition that